Neither failure of treatment nor increased deaths stop the Spaceship of Fools that gene therapy is! Despite consistent failures to produce any medicinal value, the FDA will expand the indication for Sarepta’s product:
Within the narrow group of patients eligible for Elevidys, demand has been high. The FDA is expected to decide by June 21 on whether to expand the eligible population based on mixed results from a confirmatory study.
Of course, the demand is high!! Doctors poisoning terminally ill boys for $4M a pop are not stupid. Famous quote by Robert Malone quoting his friend Steve Hatfill - “they are going to die anyway!” So, what’s the big deal, folks? $cience needs to experiment on somebody! For the greater good!
In other news, Gilead, the maker of hospital murder weapon Remdesivir has a newly-manufactured gene-therapy caused $4.9B whole in their pipeline, having recently terminated their monoclonal antibody program for cancer due to increased deaths.
No comments:
Post a Comment